Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 4
2015 4
2016 12
2017 26
2018 40
2019 38
2020 33
2021 47
2022 77
2023 108
2024 106
2025 152
2026 91

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

637 results

Results by year

Filters applied: . Clear all
Page 1
European expert consensus statement on the systemic treatment of alopecia areata.
Rudnicka L, Arenbergerova M, Grimalt R, Ioannides D, Katoulis AC, Lazaridou E, Olszewska M, Ovcharenko YS, Piraccini BM, Prohic A, Rakowska A, Reygagne P, Richard MA, Soares RO, Starace M, Vañó-Galvan S, Waskiel-Burnat A. Rudnicka L, et al. J Eur Acad Dermatol Venereol. 2024 Apr;38(4):687-694. doi: 10.1111/jdv.19768. Epub 2024 Jan 2. J Eur Acad Dermatol Venereol. 2024. PMID: 38169088 Review.
Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older. Both are EMA-approved for patients with severe …
Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adu …
Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
Zhou C, Li X, Wang C, Zhang J. Zhou C, et al. Clin Rev Allergy Immunol. 2021 Dec;61(3):403-423. doi: 10.1007/s12016-021-08883-0. Epub 2021 Aug 17. Clin Rev Allergy Immunol. 2021. PMID: 34403083 Review.
Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in hair loss, that affects up to 2% of the general population. ...Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as J …
Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease, resulting in hair loss, that affects up to 2% of …
Janus kinase inhibitors for alopecia areata.
King BA, Craiglow BG. King BA, et al. J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049. J Am Acad Dermatol. 2023. PMID: 37591562 Review.
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. ...Here, we briefly review the history of and rationale for JAK inhibitor trea …
Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, mod …
Alopecia Areata: Current Treatments and New Directions.
Dahabreh D, Jung S, Renert-Yuval Y, Bar J, Del Duca E, Guttman-Yassky E. Dahabreh D, et al. Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22. Am J Clin Dermatol. 2023. PMID: 37606849 Review.
Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the hair follicle level. ...Given the recent US FDA approval of baricitinib and ritlecitinib, Janus kinase (JAK) inhibitor …
Alopecia areata is an autoimmune hair loss disease that is non-scarring and is characterized by chronic inflammation at the ha …
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
BACKGROUND: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, for which treatments are limited. Baricitinib, an oral, selective, reversible inhibitor of Janus kinases 1 and 2, may interru …
BACKGROUND: Alopecia areata is an autoimmune condition characterized by rapid hair loss in the scalp, eyebrows, and eyelashes, …
JAK inhibitor: Introduction.
Raychaudhuri SP, Raychaudhuri SK. Raychaudhuri SP, et al. Indian J Dermatol Venereol Leprol. 2023 Sep-Oct;89(5):688-690. doi: 10.25259/IJDVL_8_2023. Indian J Dermatol Venereol Leprol. 2023. PMID: 37609754 Free article. Review.
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. ...In this symposium we have provided a broad perspective on the use of …
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling sy …
Treatment of pediatric alopecia areata: A systematic review.
Barton VR, Toussi A, Awasthi S, Kiuru M. Barton VR, et al. J Am Acad Dermatol. 2022 Jun;86(6):1318-1334. doi: 10.1016/j.jaad.2021.04.077. Epub 2021 Apr 30. J Am Acad Dermatol. 2022. PMID: 33940103 Free PMC article.
BACKGROUND: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. ...More clinical trials and comparative studies are needed to further guide management of pediatric AA and to promote the pote …
BACKGROUND: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children …
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R. Xing L, et al. Nat Med. 2014 Sep;20(9):1043-9. doi: 10.1038/nm.3645. Epub 2014 Aug 17. Nat Med. 2014. PMID: 25129481 Free PMC article.
Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. ...Systemically administered pharmacological inhibitors of Janus kinase (JAK) family protein tyrosine kinases, downstream effectors …
Alopecia areata (AA) is a common autoimmune disease resulting from damage of the hair follicle by T cells. ...Systemically adm …
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1).
King B, Senna MM, Mesinkovska NA, Lynde C, Zirwas M, Maari C, Prajapati VH, Sapra S, Brzewski P, Osman L, Hanna S, Wiseman MC, Hamilton C, Cassella J. King B, et al. J Am Acad Dermatol. 2024 Nov;91(5):880-888. doi: 10.1016/j.jaad.2024.06.097. Epub 2024 Jul 23. J Am Acad Dermatol. 2024. PMID: 39053611 Free article. Clinical Trial.
BACKGROUND: Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase (JAK) inhibitors, including deuruxolitinib, have previously demonstrated significant hair regrowth in AA. ...
BACKGROUND: Alopecia areata (AA) is a hair loss disorder that can seriously impact quality of life. Janus kinase …
An overview of JAK/STAT pathways and JAK inhibition in alopecia areata.
Lensing M, Jabbari A. Lensing M, et al. Front Immunol. 2022 Aug 30;13:955035. doi: 10.3389/fimmu.2022.955035. eCollection 2022. Front Immunol. 2022. PMID: 36110853 Free PMC article. Review.
Alopecia Areata (AA) is a common autoimmune disease characterized by non-scarring hair loss ranging from patches on the scalp to complete hair loss involving the entire body. ...Demonstrated efficacy from large-scale clinical trials of the JAK inhibitor …
Alopecia Areata (AA) is a common autoimmune disease characterized by non-scarring hair loss ranging from patches on the scalp …
637 results